BioMarin Pharmaceutical | BMRN - Sales Revenues

Stock Price
51.81
Daily Change
-1.43 -2.69%
Monthly
-4.23%
Yearly
-12.59%
Q2 Forecast
50.77

BioMarin Pharmaceutical reported $766M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
Bayer EUR 13.41B 1.97B Mar/2026
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Insmed USD 305.96M 42.16M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Moderna USD 389M 289M Mar/2026
Neurocrine Biosciences USD 811M 5.5M Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 12.14B 65M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026